Long-term efficacy of sensor-augmented pump therapy (Minimed 640G system) combined with a telemedicine follow-up in patients with type 1 diabetes: A real life study

IF 4.2 Q1 ENDOCRINOLOGY & METABOLISM Journal of Clinical and Translational Endocrinology Pub Date : 2022-12-01 DOI:10.1016/j.jcte.2022.100306
Léonie Makuété Notemi , Lamia Amoura , Fatéma Fall Mostaine , Laurent Meyer , Dominique Paris , Samy Talha , Julien Pottecher , Laurence Kessler
{"title":"Long-term efficacy of sensor-augmented pump therapy (Minimed 640G system) combined with a telemedicine follow-up in patients with type 1 diabetes: A real life study","authors":"Léonie Makuété Notemi ,&nbsp;Lamia Amoura ,&nbsp;Fatéma Fall Mostaine ,&nbsp;Laurent Meyer ,&nbsp;Dominique Paris ,&nbsp;Samy Talha ,&nbsp;Julien Pottecher ,&nbsp;Laurence Kessler","doi":"10.1016/j.jcte.2022.100306","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>Evaluate the efficacy of a new modality of insulin therapy associating both the sensor-augmented pump therapy with predictive low-glucose management (SAP-PLGM) and a telemedicine follow-up in patients with Type 1 diabetes (T1D) in a real-life setting.</p></div><div><h3>Methods</h3><p>T1D adults under Minimed 640G system with a telemedicine follow-up for glucose management were included in a retrospective study. The primary endpoint was HbA1c while continuous glucose monitoring parameters (CGM) and treatment compliance were the secondary endpoints. These parameters were analyzed according to the therapeutic indication, HbA1c ≥ 8 % (Group<!--> <!-->A) or severe hypoglycemic events (Group<!--> <!-->B) and in patients switched to SAP-PLGM therapy.</p></div><div><h3>Results</h3><p>62<!--> <!-->patients were analyzed with a 28 ± 12 months of follow-up. In Group<!--> <!-->A, HbA1c decreased from 8.3 ± 0.4 % to 7.7 ± 0.7 % (<em>p</em> &lt; 0.05) and to 7.9 ± 0.3 % (<em>p</em> &lt; 0.05) after 2 and 3 years, respectively. In patients switched to SAP-PLGM therapy, HbA1c decreased from 7.7 ± 0.7 % to 7.2 ± 0.8 % (<em>p</em> &lt; 0.05) at 2 years. After 6 months, the time-below-range (&lt;70 mg/dL) decreased from 2.1 % [0.6–4] to 1.1 % [0.3–2.6] (<em>p</em> &lt; 0.05). Severe hypoglycemic events decreased from 1.62 to 0.5<!--> <!-->events/patient/year in Group<!--> <!-->B (p &lt; 0.05). At 3 years, treatment compliance was 92 % [70–97] in the total population.</p></div><div><h3>Conclusions</h3><p>Long-term real-life treatment with the SAP-PLGM therapy combined with telemedicine was associated with improved glycemic control in T1D, along with high treatment compliance.</p></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"30 ","pages":"Article 100306"},"PeriodicalIF":4.2000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/02/d9/main.PMC9550647.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical and Translational Endocrinology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S221462372200014X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Objective

Evaluate the efficacy of a new modality of insulin therapy associating both the sensor-augmented pump therapy with predictive low-glucose management (SAP-PLGM) and a telemedicine follow-up in patients with Type 1 diabetes (T1D) in a real-life setting.

Methods

T1D adults under Minimed 640G system with a telemedicine follow-up for glucose management were included in a retrospective study. The primary endpoint was HbA1c while continuous glucose monitoring parameters (CGM) and treatment compliance were the secondary endpoints. These parameters were analyzed according to the therapeutic indication, HbA1c ≥ 8 % (Group A) or severe hypoglycemic events (Group B) and in patients switched to SAP-PLGM therapy.

Results

62 patients were analyzed with a 28 ± 12 months of follow-up. In Group A, HbA1c decreased from 8.3 ± 0.4 % to 7.7 ± 0.7 % (p < 0.05) and to 7.9 ± 0.3 % (p < 0.05) after 2 and 3 years, respectively. In patients switched to SAP-PLGM therapy, HbA1c decreased from 7.7 ± 0.7 % to 7.2 ± 0.8 % (p < 0.05) at 2 years. After 6 months, the time-below-range (<70 mg/dL) decreased from 2.1 % [0.6–4] to 1.1 % [0.3–2.6] (p < 0.05). Severe hypoglycemic events decreased from 1.62 to 0.5 events/patient/year in Group B (p < 0.05). At 3 years, treatment compliance was 92 % [70–97] in the total population.

Conclusions

Long-term real-life treatment with the SAP-PLGM therapy combined with telemedicine was associated with improved glycemic control in T1D, along with high treatment compliance.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
1型糖尿病患者传感器增强泵治疗(Minimed 640G系统)联合远程医疗随访的长期疗效:一项现实生活研究
目的评估一种新的胰岛素治疗模式,将传感器增强泵治疗与预测低血糖管理(SAP-PLGM)和远程医疗随访相结合,在现实生活中治疗1型糖尿病(T1D)患者。方法回顾性研究采用minimem640g系统并进行远程医疗随访的成人血糖管理。主要终点是HbA1c,而连续血糖监测参数(CGM)和治疗依从性是次要终点。根据治疗指征,HbA1c≥8% (A组)或严重低血糖事件(B组)以及切换到SAP-PLGM治疗的患者,对这些参数进行分析。结果对62例患者进行分析,随访28±12个月。在A组中,糖化血红蛋白下降从8.3±0.4%到7.7±0.7% (p & lt;0.05)和7.9±0.3% (p <2、3年后分别为0.05)。在改用SAP-PLGM治疗的患者中,HbA1c从7.7±0.7%降至7.2±0.8% (p <0.05)。6个月后,低于时限(70 mg/dL)从2.1%[0.6-4]降至1.1% [0.3-2.6](p <0.05)。B组严重低血糖事件从1.62例/例/年降至0.5例/例/年(p <0.05)。3年时,治疗依从性为92%[70-97]。结论SAP-PLGM联合远程医疗的长期现实治疗可改善T1D患者的血糖控制,且治疗依从性高。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.10
自引率
0.00%
发文量
24
审稿时长
16 weeks
期刊最新文献
Eating habits and carotenoid skin content among children based on their attendance at the school meals: A cross-sectional pilot study Glucagon-like peptide1 receptor agonist treatment of cystic fibrosis-related diabetes complicated by obesity: A cases series and literature review The bio-artificial pancreas to treat type 1 diabetes: Perspectives from healthcare professionals in the Netherlands Clinical characteristics of Ketosis Prone Diabetes: Evaluating diagnosis and management practices in a real-life setting Association between incretin-based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: A large population-based matched cohort study
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1